Leukocare AG hosted a roundtable titled From Data to Decisions: Computational Strategies for De-Risking Drug Product Development at HubXchange in San Francisco.

For over 20 years, Leukocare has been trusted by pharmaceutical companies, mid-sized biotech firms, and innovative biotechs for our Quality by Design-driven approach to formulation development. Our proven track record includes advancing companies into clinics, filing BLAs, and enabling patent potential, demonstrating our commitment to the successful development of cutting-edge therapies. Our strength lies in combining strong formulation expertise with data science and statistical approaches, ensuring a systematic, evidence-driven path forward. With extensive experience in both liquid and lyophilized formulation development for proteins, monoclonal antibodies (mAbs), viral vectors, and viruses, we are equipped to tackle the most complex challenges combining 100+ regulatory approved excipients. However, our greatest asset is our adaptability. We remain agile, responding quickly to changes in the regulatory landscape and evolving client needs. By combining scientific expertise with a deep understanding of regulatory requirements and the latest industry advancements, we ensure that our clients are always a step ahead. Typical projects include: • Molecular Modeling and Benchmarking • Pre-Formulation • QbD Formulation Development and Optimization • Process Development and Transfer • IP Support We believe that a great formulation is not just about scientific knowledge; it’s about relevant data, an in-depth understanding of regulatory and industry standards, and the ability to adapt quickly to the changing landscape of drug development. Let’s connect to explore how we can help advance your drug product developments. You can reach out by: • Messaging us on LinkedIn to start a conversation. • Visiting our website to learn more about our services and get in touch with our team. • Emailing us directly at info@leukocare.com for personalized support.